| | ADDICTION RECOVERY AMENDMENTS |
|-----|--|
| | 2017 GENERAL SESSION |
| | STATE OF UTAH |
| | Chief Sponsor: Karen Mayne |
| | House Sponsor: |
| LC | ONG TITLE |
| Ge | neral Description: |
| | This bill amends the Utah Controlled Substances Act. |
| Hi | ghlighted Provisions: |
| | This bill: |
| | defines terms; and |
| | requires the Division of Occupational and Professional Licensing to: |
| | • establish guidelines for the issuance of a prescription for an opiate antagonist |
| alo | ing with a prescription for an opiate; and |
| | report on the guidelines to the Health and Human Services Interim Committee. |
| Mo | oney Appropriated in this Bill: |
| | None |
| Ot | her Special Clauses: |
| | None |
| Uta | ah Code Sections Affected: |
| EN | JACTS: |
| | 58-37-19 , Utah Code Annotated 1953 |
| Ве | it enacted by the Legislature of the state of Utah: |
| | Section 1. Section 58-37-19 is enacted to read: |



58-37-19. Coprescription guidelines.

27

S.B. 258 02-23-17 9:55 AM

| 28 | (1) As used in this section: |
|----|--|
| 29 | (a) "Controlled substance prescriber" means the same as that term is defined in Section |
| 30 | <u>58-37-6.5.</u> |
| 31 | (b) "Coprescribe" means to issue a prescription for an opiate antagonist with a |
| 32 | prescription for an opiate. |
| 33 | (c) "Opiate antagonist" means naloxone hydrochloride or any similarly acting drug that |
| 34 | is not a controlled substance and that is approved by the federal Food and Drug Administration |
| 35 | for the diagnosis or treatment of an opiate-related drug overdose. |
| 36 | (2) The division shall, in consultation with the Physicians Licensing Board created in |
| 37 | Section 58-67-201, the Utah State Board of Pharmacy created in Section 58-17b-201, and the |
| 38 | Department of Health created in Section 26-1-4, establish by rule, made in accordance with |
| 39 | Title 63G, Chapter 3, Utah Administrative Rulemaking Act, scientifically based guidelines for |
| 40 | controlled substance prescribers to coprescribe an opiate antagonist to a patient. |
| 41 | (3) The division shall report to the Health and Human Services Interim Committee |
| 42 | before October 30, 2017, regarding the guidelines established under Subsection (2). |
| 43 | (4) The report described in Subsection (3) shall include: |
| 44 | (a) established rules regarding the coprescription of an opiate antagonist to a patient; |
| 45 | <u>and</u> |
| 46 | (b) an analysis of: |
| 47 | (i) the application of the rules; and |
| 48 | (ii) the impact of the rules. |
| 49 | (5) This section does not create a duty or standard of care for a controlled substance |
| 50 | prescriber to prescribe an opiate antagonist |

Legislative Review Note Office of Legislative Research and General Counsel